Active U.S. drug shortages stood at 225 at the end of the third quarter, similar to the past three quarters, according to the American Society of Health-System Pharmacists. The 87 new shortages reported through September nearly equal the 89 reported for all of 2025, and chemotherapy shortages in particular have outlasted drugmakers’ resupply estimates. The FDA’s database continues to reflect new discontinuations weekly.
Here are 11 recent shortage and discontinuation listings, according to the FDA database:
- Cefazolin in dextrose injection: Baxter Healthcare is discontinuing manufacture of its 1-gram/50-milliliter, 2-gram/100-milliliter and 3-gram/150-milliliter premixed injections, the FDA said Oct. 30.
- Cefepime hydrochloride injection: Baxter is discontinuing its 1-gram/50-milliliter and 2-gram/100-milliliter cefepime in plastic containers, the FDA said Oct. 30. Fresenius Kabi discontinued its 1-gram and 2-gram vials in February.
- Ceftriaxone sodium injection: Baxter is discontinuing its 1-gram/50-milliliter and 2-gram/100-milliliter ceftriaxone in plastic containers, the FDA said Oct. 30.
- Ciprofloxacin hydrochloride and hydrocortisone otic suspension/drops: Sandoz is discontinuing manufacture of Cipro 0.2%/1% otic suspension under NDC 66758-087-70, the FDA said Oct. 30. An authorized generic is available under NDC 0781-6218-70.
- Metformin hydrochloride extended-release tablets: Mylan, a Viatris company, is discontinuing its 500-milligram and 1,000-milligram tablets as a business decision, the FDA said Oct. 22.
- Carboplatin injection: The FDA updated its listing Oct. 20 for this long-running shortage, which dates to 2023, adding Teyro Labs, which has four presentations available. Presentations from Accord, Eugia, Fresenius Kabi, Gland Pharma, Hospira and Teva remain unavailable or in limited supply, with recovery estimates ranging from late 2026 to March 2027 for Hospira and December 2028 for one Teva presentation. The FDA cites increased demand, manufacturing delays and shipping delays.
- Enoxaparin sodium injection: Sanofi is discontinuing manufacture for the U.S. market of all presentations of Lovenox and its enoxaparin sodium injection, the FDA said Oct. 20. The decision is not related to safety or quality, FDA-approved generics are available and the last lot is expected to expire in March 2029.
- Leuprolide acetate injection: Amneal Pharmaceuticals is discontinuing its 14-milligram/2.8-milliliter injection as a business decision, the FDA said Oct. 20.
- Molnupiravir capsules: Merck is discontinuing manufacture of Lagevrio 200-milligram capsules, the FDA said Oct. 20.
- Lamivudine tablets: ViiV Healthcare is discontinuing Epivir 150-milligram and 300-milligram tablets, the FDA said Oct. 19. ViiV expects to cease distribution around April 15, 2027.
- Vigabatrin tablets: Hikma Pharmaceuticals is discontinuing its 500-milligram tablets as a business decision, the FDA said Oct. 16.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
